1. Home
  2. LANV vs MXCT Comparison

LANV vs MXCT Comparison

Compare LANV & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lanvin Group Holdings Limited

LANV

Lanvin Group Holdings Limited

N/A

Current Price

$0.91

Market Cap

115.8M

Sector

Finance

ML Signal

N/A

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.45

Market Cap

136.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LANV
MXCT
Founded
2015
1999
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
136.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
LANV
MXCT
Price
$0.91
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.11
AVG Volume (30 Days)
14.9K
★ 1.1M
Earning Date
08-26-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.33
$15.53
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.79
$0.64
52 Week High
$2.31
$1.81

Technical Indicators

Market Signals
Indicator
LANV
MXCT
Relative Strength Index (RSI) 45.15 69.59
Support Level N/A $1.15
Resistance Level $1.13 $1.54
Average True Range (ATR) 0.06 0.07
MACD 0.00 0.05
Stochastic Oscillator 60.78 85.69

Price Performance

Historical Comparison
LANV
MXCT

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: